¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-22
±³À°ÀÏÀÚ : 2019-11-22
±³À°Àå¼Ò : Àá½Ç ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»·ë  
±³À°ÁÖÁ¦ : 2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ 
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@naver.com      
±³À°Á¾·ù : ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 10 ½Ã°£ 25ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï(Àü¹®ÀÇ): 5¸¸¿ø ÇöÀåµî·Ï(Àü¹®ÀÇ): 7¸¸¿ø ÇöÀåµî·Ï(Àü°øÀÇ/Çлý/ÀüÀÓÀÇ/°£È£»ç/±âŸ): 5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:25~09:50 Multiplexed omics approach in lung cancer research  ±èÅÂÁ¤(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:50~10:15 Towards successful cancer vaccine development  ±èÁß±Ô(ÆèÅä¹ÙÀÌ¿À¸Þµå) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 10:15~10:40 Cell and gene therapy for lung cancer  Sam Janes(University College London Hospitals) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:00~09:25 Oncologic outcomes of segmentectomy in early lung cancer  ±èÈ«°ü(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:25~09:50 Application of navigation bronchoscopy in lung cancer surgery  ¹ÚÀαÔ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:50~10:15 Single Port Lung Cancer Surgery  ±èÇö±¸(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 10:15~10:40 Image-guided surgery in lung cancer  ÀÌ⿵(¿¬¼¼ÀÇ´ë) 
È޽Ġ11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 10:40~11:10 È޽Ġ () 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:10~11:50 Whole genomic landscape of pre-invasive lung cancer lesions  Sam Janes(University College London Hospitals) 
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:50~12:00 Q & A  Sam Janes(University College London Hospitals) 
½Ä»ç 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:00~12:40 Luncheon Symposium II.  °­ÁøÇü(°¡Å縯ÀÇ´ë) 
È޽Ġ11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:40~13:00 ÃÑȸ  () 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 13:00~13:20 Æó¾Ïº´±âÁ¶»ç»ç¾÷(KALC R)ÀÇ °æ°ú ¹× ¹ßÀü ¹æÇâ  ÃÖâ¹Î(¿ï»êÀÇ´ë) 
È޽Ġ11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 13:20~13:40   () 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 13:40~14:05 Overcoming Resistance to first-line osimertinib in EGFR-mutant lung cancer  ÀÌÀ±±Ô(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:05~14:30 Emerging therapies for Resistance of ALK-Targeted Therapies  À̽·æ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:30~14:55 Resistance Mechanisms to BRAF/MEK inhibition in BRAF-mutant lung cancer  À±½Å±³(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:55~15:20 Emerging Rare Targets beyond EGFR/ALK/ROS1/BRAF in Lung Cancer  ±èÀ¯Á¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 13:40~14:05 Lung cancer screening in Korea: Potential future directions  Àå½ÂÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:05~14:30 Lung cancer screening in Korea: Lessons the K-LUCAS  ±è¿­(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:30~14:55 Lung cancer screening with low-dose CT: What we have learned  ±¸Áø¸ð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:55~15:20 Lung-RADS: All you need to know  ±èÇý¿µ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 15:20~15:40 History and current status of the new tobacco products  ±èÀ¯ÀÏ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 15:40~16:00 Safety assessment of the new tabacco products  ¹ÚÇýÁ¤(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 16:00~16:20 Regulatory strategies in perspective of population science for the new tobacco products  ±èÈñÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1 15:20~16:20 Oral Presentation III.  À̰DZ¹(±¹¸³¾Ï¼¾ÅÍ) 
È޽Ġ11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 16:20~16:50 È޽Ġ () 
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 16:50~17:20 Topic I. Local Treatment for Oligometastases  Á¶¼®±â(¼­¿ïÀÇ´ë) 
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 17:20~17:50 Topic II. Harmonizing systemic therapy with local treatment for oligometastases  È«¹ÎÈñ(¿¬¼¼ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »ï¼º¼­¿ïº´¿ø ´ëÇÑû¼Ò³âÁ¤½ÅÀÇÇÐȸ û¼Ò³â Á¤½ÅÄ¡·á: ¿øÄ¢°ú ½ÇÁ¦ : 2019-11-22
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ(¸Á¸·ÀÇ ÃֽŠÁö°ß) : 2019-11-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
287 ¼­¿ï 2018 ´ëÇÑâ»óÇÐȸ ±³À°½ÉÆ÷Áö¾ö : 2018-09-29 0 628 2018-07-28
286 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(CSC treatment update) : 2018-09-28 0 1,118 2018-07-28
285 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) ÇǺΠÇ÷°ü Áúȯ 2) »ö¼Ò ÀÌ»óÁõ : 2018-09-27 0 794 2018-07-28
284 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(Æó¼â°¢ ³ì³»Àå) : 2018-09-21 0 1,437 2018-07-28
283 ´ë±¸ ´ëÇѽÅÀåÇÐȸ ´ë±¸-°æºÏÁöȸ ¿¬¼ö °­Á : 2018-09-20 0 682 2018-07-28
282 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-20 0 421 2018-07-28
281 ¼­¿ï [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] 4Â÷ »ê¾÷Çõ¸í°ú ÀÇ·áÀÇ ¹Ì·¡ : 2018-09-20 0 658 2018-07-28
280 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ Á¦5Â÷ ȸ¿ø¿¬¼ö±³À°(Áø´Ü¸í¿¡ µû¸¥ ÀûÀýÇÑ Ã³¹æ) : 2018-09-20 0 893 2018-07-28
279 °­¿ø ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Á¦ 130ȸ ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2018-09-19 0 761 2018-07-28
278 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-19 0 513 2018-07-28
277 ¼­¿ï ¼ÛÆı¸(4Â÷) °³¿øÀÇ ¿¬¼ö±³À°(¿äÅëȯÀÚ, °ñ´Ù°øÁõ) : 2018-09-18 0 520 2018-07-28
276 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¾È°úÁö¿ªÀÇ»ç Áý´ãȸ : 2018-09-18 0 551 2018-07-28
275 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø ³ì³»Àå : 2018-09-18 0 670 2018-07-28
274 ´ë±¸ ´ëÇѽŰæ°úÇÐȸ ´ë°æÁöȸ - ´ë°æ½Å°æ°úÀÇ»çȸ °øµ¿ ½ÉÆ÷Áö¿ò : 2018-09-18 0 1,524 2018-07-28
273 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-18 0 638 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷